Table of Contents
Most therapies for inflammatory bowel disease (IBD) appear safe for patients with chronic kidney disease (CKD), but careful medication management is crucial, according to a new review published in Aliment Pharmacol Ther.
The intersection of IBD and CKD is becoming increasingly common, demanding a more nuanced understanding of how IBD medications impact renal health.A complete review of current evidence reveals that while many IBD treatments are generally well-tolerated even in advanced kidney disease, a “tailored approach” is essential to optimize effectiveness and minimize harm.Clinicians treating patients with both conditions must be acutely aware of potential effects on renal metabolism.
Biologics Show Promise, Conventional Therapies Require Caution
the review suggests that biologic therapies – medications derived from living organisms – demonstrate a favorable safety profile in patients with CKD, including those on renal replacement therapy (dialysis). These therapies, targeting components of the immune system, are largely metabolized through cellular processes, reducing the reliance on kidney function for elimination. However, the authors caution that conventional therapies and small molecule drugs, such as Janus kinase (JAK) inhibitors, require greater vigilance.
Specific Medication Guidance: A Deep Dive
The review provides detailed guidance on managing various IBD medication classes in the context of CKD:
Corticosteroids: lowest Effective Dose is Key
While dose adjustments aren’t typically needed in advanced kidney disease,including dialysis,the authors recommend using the lowest effective dose and shortest duration of corticosteroid therapy. Thay also suggest considering budesonide over prednisolone in patients with advanced kidney disease due to its lower risk of systemic side effects. Monitoring blood glucose and blood pressure remains crucial for patients with pre-existing risk factors.
Aminosalicylates: Regular Monitoring Essential
For patients receiving 5-aminosalicylic acid (5-ASA) compounds like mesalazine (mesalamine) and sulfasalazine, regular monitoring of renal function is advised – at baseline, three months, and then every 12 months. Maintaining adequate fluid intake is also critical to prevent dehydration. Dose reductions may be necessary based on eGFR.
S1P Receptor Modulators: Cautious Approach Advised
While strong evidence suggests no dose adjustment is needed for S1P receptor modulators in CKD, including ESKD, the authors recommend “cautious use and robust clinical judgement” due to a lack of real-world studies. No published data currently exists on S1P inhibitors in patients requiring dialysis.
The Path Forward: Personalized Care and Diligent Monitoring
The authors conclude that managing IBD in patients with CKD requires a personalized approach, emphasizing “diligent surveillance of renal function to optimise treatment efficacy and minimise renal compromise.” As the number of patients with both IBD and CKD continues to rise, this guidance will be critical for clinicians striving to deliver optimal care.
Reference: Chen L, Srinivasan A, Choy SW, Van J, Habeeb H, Nguyen A, Vasudevan A.Prescribing inflammatory bowel disease medications in chronic kidney disease: a practical guide. Aliment Pharmacol Ther.2025;62(4):400-418. doi:10.1111/apt.70262
